These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 26924475

  • 1. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [Abstract] [Full Text] [Related]

  • 2. [Not Available].
    Viardot A.
    Ther Umsch; 2017 Jun; 74(8):423-431. PubMed ID: 29461148
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD.
    J Diabetes Complications; 1994 Jun; 8(4):201-3. PubMed ID: 7833494
    [Abstract] [Full Text] [Related]

  • 6. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M.
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [Abstract] [Full Text] [Related]

  • 7. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B, Li YH, Chan P.
    Expert Opin Pharmacother; 2022 Dec; 23(17):1869-1877. PubMed ID: 36300277
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, Andrews C, Barnett A.
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [Abstract] [Full Text] [Related]

  • 9. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P, Bouma A, Landman GW, Groenier KH, Bilo H, Kleefstra N, van Hateren KJ.
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract] [Full Text] [Related]

  • 10. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS, Eurich DT, Senthilselvan A, Qiu W, Simpson SH.
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [Abstract] [Full Text] [Related]

  • 11. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS.
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P, Ciccone G.
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gliclazide modified release: its place in the therapeutic armamentarium.
    Crepaldi G, Fioretto P.
    Metabolism; 2000 Oct; 49(10 Suppl 2):21-5. PubMed ID: 11078472
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
    Li GW, Pan CY, Gao Y, Yuan SY, Yang WY, Xing XY, Tian H, Guo XH, Li HB.
    Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K.
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [Abstract] [Full Text] [Related]

  • 19. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I.
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [Abstract] [Full Text] [Related]

  • 20. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M, Tronko M, Kravchenko V, Kovtun V.
    Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.